Compare CNK & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNK | AMLX |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.8B |
| IPO Year | 2007 | 2021 |
| Metric | CNK | AMLX |
|---|---|---|
| Price | $38.50 | $26.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $40.27 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,115,000,000.00 | $380,786,000.00 |
| Revenue This Year | $16.02 | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.15 | ★ 1612.94 |
| 52 Week Low | $21.60 | $10.83 |
| 52 Week High | $39.09 | $41.14 |
| Indicator | CNK | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 63.48 | 36.31 |
| Support Level | $36.28 | $26.04 |
| Resistance Level | $38.96 | $28.60 |
| Average True Range (ATR) | 1.12 | 1.18 |
| MACD | 0.21 | -0.19 |
| Stochastic Oscillator | 73.38 | 12.32 |
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres. Cinemark manages its business under two reportable segments: U.S. markets and international markets. The majority of its revenue is generated from the U.S. markets segment.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.